4
Changes in Ownership
Vaxcyte, Inc. Filed Acc 0001649094-24-000126
PRESIDENT AND CFO sold 8,000 shares at an average $88.78 ($710,249)
- PRESIDENT AND CFO acquired 8,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| GUGGENHIME ANDREW PRESIDENT AND CFO | 2024-12-18 | Option exercise 10b5-1 | +8,000 | $5.35 | $42,800 | 117,491 | D |
| GUGGENHIME ANDREW PRESIDENT AND CFO | 2024-12-18 | Sale 10b5-1 | −1,190 | $87.26 | $103,835 | 116,301 | D |
| GUGGENHIME ANDREW PRESIDENT AND CFO | 2024-12-18 | Sale 10b5-1 | −3,373 | $88.70 | $299,188 | 112,928 | D |
| GUGGENHIME ANDREW PRESIDENT AND CFO | 2024-12-18 | Sale 10b5-1 | −3,157 | $89.31 | $281,958 | 109,771 | D |
| GUGGENHIME ANDREW PRESIDENT AND CFO | 2024-12-18 | Sale 10b5-1 | −280 | $90.24 | $25,267 | 109,491 | D |
| Derivatives | |||||||
| GUGGENHIME ANDREW PRESIDENT AND CFO | 2024-12-18 | Option exercise · Stock Option (right to buy) 10b5-1 | −8,000 | 262,827 | D | ||
| Open-market sales · 8,000 sh · avg $88.78 · $710,249 | |||||||
Loading xslF345X05/wk-form4_1734642427.xml…